Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT07610655
- Status
- Recruiting
Conditions
- Cognitive Impairment
- Depression
- Post Operative Delirium
- Vagus Nerve Stimulation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Transcutaneous vagal nerve stimulation — DEVICEThe tcVNS device utilized in this study is not an implanted device, but rather is solely operated outside of the body by affixing it around the patient's ear. The device delivers stimulation of the vagus nerve at designated intensity, interval, and frequency.
- Sham (No Treatment) — DEVICEThe stimulator is flipped upside down so that the participant does not receive stimulation of the vagal nerve.
Study Details
This study will examine whether noninvasive, transcutaneous vagal nerve stimulation (tcVNS) can help restore consciousness in patients in the operating room and the Post Anesthesia Care Unit (PACU). The study will also investigate if tcVNS can expedite discharge from the PACU and examine whether tcVNS administerd in the PACU helps reduce delirium and depression after surgery. The study will also evaluate whether tcVNS speeds cognitive recovery from emergence of anesthesia and surgery.
Key Dates
- Start date
- Apr 23, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2028
- Completion
- May 31, 2029
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: tcVNS Stimulation (Intervention)Transcutaneous vagal nerve stimulation (tcVNS)
- Sham Comparator: Sham tcVNS stimulation (Control)Sham transcutaneous vagal nerve stimulation (Sham tcVNS)
Primary Outcome Measure
Aim 1: Primary Endpoint 1: Determine if administering auricular tcVNS enhances the speed of recovery of anesthesia. [ Time Frame: 24 Hours ]
Central Contacts
- Jordan Wood, BS3126950915
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | Charles Hogue, MD (PRINCIPAL_INVESTIGATOR) Ravindra A Gupta, MD (SUB_INVESTIGATOR) John Bebawy, MD (SUB_INVESTIGATOR) Eyal Kimchi, MD, PhD (SUB_INVESTIGATOR) Jacqueline Morano, MD (SUB_INVESTIGATOR) Jamie Uejima, MD (SUB_INVESTIGATOR) Kimberly Klafta, MD (SUB_INVESTIGATOR) |
Find similar trials in Chicago, IL
By condition
By specialty
By research site
Related Studies
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.PHASE3 · Recruiting · AbbVie · Bentonville, Arkansas
- Evaluating the Impact of Focused Muscle Contraction Therapy in U.S. VeteransRecruiting · University of Illinois at Chicago · Chicago, Illinois
- BEhavioral Health Stratified Treatment (BEST) Study for Youth With Intellectual and/or Developmental Disabilities (IDD)Enrolling By Invitation · University of Illinois at Chicago · Chicago, Illinois
- Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog TrialRecruiting · Northwestern University · Chicago, Illinois